Chronic Immune-Related Adverse Events Common in Anti-PD-1 Therapy for Melanoma

Source: Dermatology Times, September 2023

Endocrine toxic effects were more likely than nonendocrine to become chronic and continue at last follow-up.

To assess the incidence, characteristics, and long-term outcomes of chronic immune-related adverse events (irAEs) caused by adjuvant anti-programmable cell death-1 (anti-PD-1) therapy, researchers conducted a retrospective, multicenter cohort study and found that irAEs were common and affected multiple organ systems.

Goodman et al collected data from 6 academic medical centers in the United States and Australia. Patients who received at least 1 dose of adjuvant anti-PD-1 therapy with at least 18 months of follow-up were included. Acute irAEs were those that arose during treatment, delayed irAES arose within 6 months of treatment cessation, and chronic irAEs were those that continued at least 3 months after treatment cessation.
READ THE ORIGINAL FULL ARTICLE